How Natriuretic Peptides Affect Fluid Clearance in the Lungs During Heart Failure

Researchers used an isolated liquid-filled lung model in rats to directly measure alveolar fluid clearance rates. Congestive heart failure was induced using the aortocaval fistula model in Sprague-Dawley rats. The expression of natriuretic peptides, Na+,K+-ATPase, sodium channels, and the ubiquitin ligase Nedd4-2 was assessed in alveolar epithelial cells. AFC was measured in sham controls, ANP-treated, BNP-treated, compensated CHF, and decompensated CHF groups.

Pulmonary edema — fluid in the lungs — is one of the most dangerous complications of heart failure and a leading cause of hospital admissions. Understanding how natriuretic peptides regulate lung fluid clearance could lead to better-targeted treatments that help the lungs clear fluid without causing harmful side effects, particularly in patients with severe decompensated heart failure.

Natriuretic peptides like ANP and BNP are already used clinically as biomarkers for heart failure severity, and synthetic BNP (nesiritide) has been used therapeutically. This study reveals a previously underappreciated effect of these peptides on lung fluid balance, which could explain why some heart failure patients develop pulmonary edema despite treatment. The finding that ANP partially restores fluid clearance in decompensated CHF suggests natriuretic peptide signaling shifts as heart failure progresses, opening the door to stage-specific therapeutic strategies.

This is an animal study using rats, and findings may not directly translate to human lung physiology. The aortocaval fistula model of heart failure does not perfectly replicate all forms of human CHF. The isolated lung model, while useful for measuring fluid clearance, removes the lungs from the context of whole-body circulation and hormonal regulation. Specific sample sizes per group are not reported in the abstract. Long-term effects of natriuretic peptide manipulation on lung function were not assessed.